iomeprol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 1463 78649-41-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iomeprol
  • iomeron
  • imeron
  • Molecular weight: 777.09
  • Formula: C17H22I3N3O8
  • CLOGP: -2.31
  • LIPINSKI: 3
  • HAC: 11
  • HDO: 7
  • TPSA: 179.66
  • ALOGS: -3.12
  • ROTB: 10

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rash maculo-papular 198.70 64.39 50 668 31846 63456458
Toxic skin eruption 168.98 64.39 37 681 12848 63475456
Acute generalised exanthematous pustulosis 168.76 64.39 36 682 11063 63477241
Drug reaction with eosinophilia and systemic symptoms 166.51 64.39 44 674 33792 63454512
Eosinophilia 128.19 64.39 33 685 22723 63465581

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 316.20 73.88 78 492 32934 34923427
Rash maculo-papular 140.15 73.88 40 530 28411 34927950
Acute kidney injury 107.68 73.88 64 506 304924 34651437
Toxic skin eruption 93.38 73.88 24 546 11361 34945000
Acute generalised exanthematous pustulosis 89.69 73.88 21 549 6755 34949606

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 466.69 58.80 122 1164 64122 79678980
Rash maculo-papular 328.10 58.80 90 1196 55988 79687114
Toxic skin eruption 253.98 58.80 61 1225 22232 79720870
Acute generalised exanthematous pustulosis 247.92 58.80 57 1229 17197 79725905
Eosinophilia 167.21 58.80 51 1235 45294 79697808
Acute kidney injury 129.88 58.80 88 1198 519316 79223786
Rash morbilliform 70.66 58.80 17 1269 6133 79736969

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AB10 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:37338 contrast media
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.56 acidic
pKa2 11.03 acidic
pKa3 11.52 acidic
pKa4 13.95 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01719 KEGG_DRUG
C0063810 UMLSCUI
CHEBI:31710 CHEBI
CHEMBL2107214 ChEMBL_ID
DB11705 DRUGBANK_ID
C057937 MESH_SUPPLEMENTAL_RECORD_UI
5859 INN_ID
17E17JBP8L UNII
3731 PUBCHEM_CID
2606484 RXNORM
19468 MMSL
d05472 MMSL
006219 NDDF
356671000 SNOMEDCT_US
395753004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-7250 INJECTION, SOLUTION 510 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-7300 INJECTION, SOLUTION 612 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-7350 INJECTION, SOLUTION 714 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-7400 INJECTION, SOLUTION 816 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-9300 INJECTION, SOLUTION 612 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-9350 INJECTION, SOLUTION 714 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 0270-9400 INJECTION, SOLUTION 816 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-725 INJECTION, SOLUTION 510 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-730 INJECTION, SOLUTION 612 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-735 INJECTION, SOLUTION 714 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-740 INJECTION, SOLUTION 816 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-930 INJECTION, SOLUTION 612 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-935 INJECTION, SOLUTION 714 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections
Iomeron HUMAN PRESCRIPTION DRUG LABEL 1 76381-940 INJECTION, SOLUTION 816 mg INTRAVASCULAR Unapproved drug for use in drug shortage 3 sections